Description: Bachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. The company was founded in 1971 and is headquartered in Bubendorf, Switzerland.
Home Page: www.bachem.com
Hauptstrasse 144
Bubendorf,
4416
Switzerland
Phone:
41 58 595 2021
Officers
| Name | Title |
|---|---|
| Mr. Thomas Meier | Chief Exec. Officer |
| Dr. Thomas Fruh | Sec. |
| Mr. Alain Schaffter | Chief Financial Officer |
| Mr. Roland Schürmann | Chief Operations Officer |
| Mr. Michael Suter | VP of Global Accounting |
| Dr. Gunther Loidl | Chief Technology Officer |
| Mr. Michael Staroverov | Group Chief Information Officer |
| Mr. Torsten Wöhr | Chief Marketing Officer |
| Dr. Christian Stähelin | Director of HR |
| Mr. Jean-Marc Fellay | VP of Fin. & HR |
Exchange: SW
Country: CH
Currency: Swiss Franc (CHF)
| Forward PE: | 46.5116 |
|---|---|
| Trailing PE: | 63.8603 |
| Price-to-Book MRQ: | 5.6857 |
| Price-to-Sales TTM: | 12.4348 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 1663 |